Celularity (CELU) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Celularity (CELU) has outperformed ImageneBio (IMA) over the past year, losing 32.1% versus a loss of 48.5%. Over five years, IMA leads with a -97.1% price change compared with -98.0% for CELU. ImageneBio is the larger company by market cap ($48.5 million vs $47.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | IMA |
|---|---|---|
| Share price | $1.46 | $4.26 |
| Market cap | $47.38M | $48.45M |
| 1-day change | -0.68% | -7.59% |
| YTD return | +31.53% | -38.26% |
| 1-year return | -32.09% | -48.49% |
| 5-year return | -97.97% | -97.07% |
| EPS (TTM) | $-2.73 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.55 | $9.10 |
| 52-week low | $0.56 | $3.94 |
| Distance from 52-week high | -42.75% | -53.19% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +322.54% |
| Average volume | 3.89M | 13.04K |
| Shares outstanding | 32.45M | 11.37M |
| Employees | 115 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed IMA by 16.4 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CELU vs IMA FAQ
Which is bigger, Celularity or ImageneBio?
ImageneBio (IMA) is larger, with a market capitalization of $48.45M compared with $47.38M for Celularity (CELU).
Which stock has performed better over the past year, CELU or IMA?
CELU returned -32.09% over the past 12 months, compared with -48.49% for IMA (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and ImageneBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Celularity and Biotechnology: Biological Products (No Diagnostic Substances) for ImageneBio.